Quick Answer
VYNE Therapeutics Inc. reported Operating Income Loss of -$29.75 million for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +31.8% in Operating Income Loss from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$5.56 million | Q2 2017: -$6.23 million | Q3 2017: -$8.34 million | Q1 2018: -$13.22 million | Q2 2018: -$9.17 million | Q3 2018: -$13.70 million | Q1 2019: -$15.88 million | Q2 2019: -$19.36 million | Q3 2019: -$23.20 million | Q4 2019: -$37.43 million | Q1 2020: -$39.89 million | Q2 2020: -$167.18 million | Q3 2020: -$23.49 million | Q4 2020: -$21.99 million | Q1 2021: -$9.76 million | Q2 2021: -$9.54 million | Q3 2021: -$10.77 million | Q1 2022: -$8.69 million | Q2 2022: -$8.29 million | Q3 2022: -$9.33 million | Q1 2023: -$5.88 million | Q2 2023: -$10.32 million | Q3 2023: -$6.23 million | Q1 2024: -$7.38 million | Q2 2024: -$10.40 million | Q3 2024: -$13.09 million | Q1 2025: -$9.20 million | Q2 2025: -$7.54 million.
- Over the full 11 years of available data (2015 to 2025), VYNE Therapeutics Inc.'s Operating Income Loss has declined by 545.6%.
- Historical annual values: Fiscal year 2025: -$29.75 million | Fiscal year 2024: -$43.64 million | Fiscal year 2023: -$29.26 million | Fiscal year 2022: -$34.30 million | Fiscal year 2021: -$38.91 million | Fiscal year 2020: -$252.55 million | Fiscal year 2019: -$95.87 million | Fiscal year 2018: -$74.89 million | Fiscal year 2017: -$29.59 million | Fiscal year 2016: -$14.33 million | Fiscal year 2015: -$4.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: